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a  b  s  t  r  a  c  t
The  2007  US  approval  for use  of live  attenuated  inﬂuenza  vaccine  (LAIV)  in  children  aged 24–59 months
included  precautions  against  use  in (1)  children  <24  months  and  children  aged  24–59  months  with (2)
asthma,  (3)  recurrent  wheezing,  and  (4) altered  immunocompetence.  A  postmarketing  commitment  was
initiated  to monitor  LAIV use  and  the  frequency  of select  safety  outcomes  in  these  cohorts.  Vaccination
rates  and  the  frequency  of  hospitalizations  or emergency  department  visits  within  42  days  after  LAIV  and
trivalent  inactivated  inﬂuenza  vaccine  (TIV)  administration  were  estimated  from  2007  to  2009  claims
data  from  a health  insurance  database.  Rates  of  LAIV  use per  10,000  child-days  among  cohorts  1,  2,
and  4 were  low  relative  to rates  among  the  LAIV-recommended  population  (2007–2008;  0.03–0.78  vs.
1.32,  2008–2009;  0.08–3.26  vs.  5.94). However,  rates  of  LAIV  use per  10,000  child-days  in cohort  3  were
similar  to rates  among  the  LAIV-recommended  population  (2007–2008;  1.55  vs. 1.32,  2008–2009;  5.01
vs.  5.94).  The  rate  of  emergency  department  visits/hospitalizations  within  42  days  of  vaccination  with
LAIV  was  the  same  as  or less  than  the  rate  within  42 days  of vaccination  with  TIV.  Less  restricted  LAIV
use  in children  with  past  wheezing  may  be related  to the  broad  deﬁnition  of  recurrent  wheezing  used  in
national  guidelines  and  the  current  study.  In the  small  number  of  nonrecommended  children  receiving
LAIV,  no safety  signals  were  identiﬁed.. Introduction
The US Centers for Disease Control and Prevention Advisory
ommittee on Immunization Practices (ACIP) recommends that all
hildren aged 6 months through 18 years receive inﬂuenza vaccine
n a yearly basis [1]. The live attenuated inﬂuenza virus vaccine
LAIV; MedImmune LLC, Gaithersburg, MD,  USA) was  approved in
he United States for use in eligible individuals aged 5–49 years of
ge in 2003. Based on additional clinical trials, LAIV was approved
or use in children 2–4 years of age in September 2007 with pre-
autions against use in children <24 months old and children 24–59
onths old with asthma, recurrent wheezing, or altered immuno-
ompetence. LAIV was not approved for use in children younger
han 24 months owing to an increased risk of medically signif-
cant wheezing in LAIV-vaccinated children 6–23 months of age
5.9% LAIV vs. 3.8% trivalent inactivated inﬂuenza vaccine [TIV])
nd an increased rate of hospitalization in LAIV-vaccinated chil-
ren 6–11 months of age (6.1% LAIV vs. 2.6% TIV) observed in a
tudy conducted in the 2004–2005 inﬂuenza season [2].
∗ Corresponding author. Tel.: +1 919 316 3812; fax: +1 919 541 7222.
E-mail  address: ptennis@rti.org (P. Tennis).
264-410X ©  2011 Elsevier Ltd. 
oi:10.1016/j.vaccine.2011.04.113
Open access under CC BY-NC-ND license.© 2011 Elsevier Ltd. 
After the 2007 approval of LAIV for use in children 24–59 months
of age, MedImmune made a commitment to the US Food and Drug
Administration to assess the frequency of use and safety of LAIV in
speciﬁc groups of children <5 years of age for whom the vaccine
is not intended. These groups included children younger than 24
months and children 24–59 months of age with asthma or recur-
rent wheezing or who  were immunocompromised. The purpose
of this study was to quantify, through 3 inﬂuenza seasons in these
populations, the rate of LAIV vaccination and to monitor emergency
department (ED) visits or hospitalizations occurring within 42 days
postvaccination with LAIV compared with that of TIV. The current
report summarizes the ﬁndings from the 2007 to 2008 and 2008 to
2009 inﬂuenza seasons.
2.  Methods
2.1. Study population
Children younger than 60 months who received LAIV or TIV dur-
ing the study period and were enrolled in a health insurance plan
Open access under CC BY-NC-ND license.with claims data captured by MarketScan® Research Data (Thom-
son Reuters, New York, NY, USA) were eligible for analysis. The
MarketScan database is a health insurance claims database that
covers approximately 17 million individuals. To protect patient
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nonymity, only the month and year of birth were available for age
etermination in the dataset available to researchers. As a result,
he ﬁrst day of the birth month was assigned as each child’s date
f birth. This ensured that all children identiﬁed as <24 months of
ge were truly younger than 24 months.
For children meeting the age criteria in either season
2007–2008 and 2008–2009), all claims from August 1 of the prior
ear (2006 and 2007, respectively) through March 31 of the sea-
on (2008 and 2009, respectively) were obtained. To deﬁne each
ohort, we analyzed the claims for each child from 12 months
efore August 1 through February 17 of the season in question,
hich was deﬁned as the cohort eligibility period. Because data
ere available only through March 31 of each season at the time
f the analysis, February 17 was chosen as the cut-off date for vac-
ination to ensure that all subjects had 42 days of postvaccination
ollow-up for evaluation of safety events. To be included, children
ere younger than 60 months as of August 1 and had to have 6
onths of insurance enrollment before August 1.
.2.  Cohort deﬁnitions
Children  contributed time to the cohort younger than 24 months
s long as they were aged <24 months. Children remained in the
ther three cohorts as long as they were 24–59 months of age
nd met  the cohort-speciﬁc disease and enrollment criteria. Chil-
ren with asthma were identiﬁed based on a claims diagnosis of
sthma; for children with a single outpatient diagnosis, a claim
or an inhaled short-acting beta-agonist (SABA) was  also required.
hildren with recurrent wheezing were identiﬁed based on a claim
or an inhaled SABA in the prior 12 months with no diagnosis
f asthma. The deﬁnition of the recurrent wheezing cohort was
esigned to reﬂect the ACIP statement that children with recurrent
heezing could be identiﬁed as children with a wheezing episode
n the past 12 months [3]. Children with immunocompromise were
dentiﬁed based on a diagnosis or therapy known to be associated
ith immuncompromise (see Supplementary Text 1 for further
laboration of cohort-speciﬁc criteria).
To provide context for the results on the 24–59-month-old
ohorts  of interest, a general population cohort was  created com-
rising children aged 24–59 months who met  the enrollment
riteria but did not meet the inclusion criteria of the other cohorts.
.3. Assessment of vaccination rates
Children vaccinated with LAIV or TIV were identiﬁed by the
orresponding procedural code (ICD-9-CM, Current Procedural Ter-
inology [CPT], or Healthcare Common Procedure Coding System
ode) or pharmacy code (National Drug Code). Because children
ould move into a new age category and enter, leave, or change
ohorts throughout the vaccination season, we used the number
f relevant vaccinations/child-days of follow-up to derive vacci-
ation frequency in each cohort. Vaccination rate was calculated
y dividing the number of children vaccinated in a cohort by the
otal child-days of follow-up within a cohort. Conﬁdence inter-
als were estimated using Episheet [4]. Follow-up started at entry
nto the cohort; end of follow-up in a cohort was  the earliest
ate on which the child (1) no longer met  the eligibility criteria
or the cohort, (2) received her or his ﬁrst LAIV or TIV vaccina-
ion, or (3) was no longer covered by a health plan that included
rescription drug coverage. Although children may  have been vac-
inated twice in accordance with recommendations for 2 doses
n previously unvaccinated children <9 years of age, all analy-
es of vaccination rate and evaluation of outcomes of interest
ncluded only the ﬁrst inﬂuenza vaccination of the season. By
oing so, we avoided double-counting subjects and minimized (2011) 4947– 4952
bias  from differential rates of second-dose receipt across vaccine
groups.
2.4. Characterization of vaccinated children
In each of the 4 cohorts we  further characterized children
who were vaccinated with LAIV or TIV. Among vaccinated chil-
dren younger than 24 months, the age distribution of the children
was assessed. Among vaccinated children with a claim indi-
cating immunosuppression, we characterized the percentage of
children qualifying for the cohort owing to a diagnosis of an
immunosuppressive condition or owing to a prescription for an
immunosuppressive medication. Because of the heterogeneity of
disease severity in children with asthma or wheezing, these cohorts
were characterized by age and the number of SABA prescriptions
and prescriptions for inhaled corticosteroid (ICS) in the preceding
12 months.
2.5. Safety assessment
Because  the primary safety objective was to describe the type
and number of ED visits or hospitalizations occurring within 42
days postvaccination in each cohort, only vaccinated children in
each cohort were followed up for the safety assessment. The vac-
cinated asthma and wheezing cohorts were combined for the
safety analysis because of the presumed similar pathophysiology
in both cohorts. An event consisted of a unique ED or hospi-
talization, and the following prespeciﬁed ED or hospitalization
claims diagnoses were deﬁned as events of interest: among chil-
dren ≤24 months of age, lower respiratory illnesses; among the
asthma and wheezing cohorts, speciﬁc lower respiratory conditions
known to exacerbate asthma and wheezing [5] (asthma-493.x,
acute bronchiolitis-466.1x, croup-464.4, inﬂuenza-487.x, pneumo-
nia 033.x, 480.x, 481, 482.x, 483.x, 484.x, 485, 486, 487.0); and
among the immunocompromised cohort, infections.
Because follow-up time was  42 days after each LAIV vaccina-
tion for all cohort members, we derived crude risks of events of
interest equal to the number of events of interest in the vaccinated
cohort divided by the number of children in the vaccinated cohort.
We generated conﬁdence intervals to indicate the precision of the
estimated risks but not for statistical testing purposes. If an ele-
vation in the frequency of events of interest was observed among
LAIV-vaccinated children, further investigation by evaluation of the
children’s speciﬁc diagnoses, medical history, timing of the event
relative to vaccination, and biological rationale was planned.
A  child could have more than 1 event of interest within
the 42-day postvaccination period. If a child visited the ED and
was hospitalized for the same condition within 24 h, only the
hospitalization was counted. As prespeciﬁed by protocol, we mon-
itored for previously unidentiﬁed safety concerns by identifying
ICD-9-CM codes occurring among ≥2 LAIV-vaccinated children
within a cohort and derived the frequency of each code among
TIV-vaccinated children in the same cohort. Frequency of all hos-
pitalization or ED visitations for any diagnosis was derived as an
indicator of the overall health status of each cohort and deﬁned as
the total number of hospitalizations or ED visits (if not associated
with hospitalization) during follow-up divided by the number of
children vaccinated. All analyses were performed using SAS® sta-
tistical software, Version 9.1.3 or higher (SAS Institute Inc., Cary,
NC, USA).3.  Results
During the 2007–2008 and 2008–2009 seasons (seasons 1 and
2), LAIV vaccination rates in those aged <24 months and those
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Table 1
Rate  of vaccination with LAIV and TIV for seasons 1 and 2.
Cohort Season 1 (2007–2008) Season 2 (2008–2009)
LAIV TIV LAIV TIV
Child-days n Vaccination ratea
(95% CI)
Child-days n Vaccination ratea
(95% CI)
n Vaccination ratea
(95% CI)
Rate
ratiob
n Vaccination ratea
(95% CI)
Rate
ratiob
Age <24 months 48,058,670 138 0.029 (0.024–0.034) 64,440,837 120,901 25.16 (25.02–25.30) 537 0.08 (0.08–0.09) 2.76 182,365 28.30 (28.17–28.43) 1.12
Age  24–59 months
Asthma 4,180,784 325 0.78 (0.70–0.87) 5,213,056 12,843 30.72 (30.19–31.25) 1327 2.55 (2.41–2.69) 3.27 16,602 31.85 (31.36–32.34) 1.04
Recurrent  wheezing 1,988,056 308 1.55 (1.38–1.73) 2,165,596 4880 24.55 (23.86–26.25) 1085 5.01 (4.72–5.32) 3.23 5054 23.34 (22.70–24.00) 0.95
Immunocompromised 193,800 12 0.62 (0.32–1.08) 272,650 634 32.71 (30.22–35.36) 89 3.26 (2.62–4.02) 5.26 801 29.38 (27.38–31.49) 0.90
General  population 88,651,792 11,696 1.32 (1.30–1.34) 108,859,733 158,215 17.85 (17.76–17.93) 64,619 5.94 (5.89–5.98) 4.50 185,947 17.08 (17.00–17.16) 0.96
LAIV: live attenuated inﬂuenza vaccine; n: number of children contributing to the numerator for each cohort; TIV: trivalent inactivated inﬂuenza vaccine.
a Rate per 10,000 child-days.
b Rate ratio of season 2 to season 1.
Table 2
Emergency department visits or hospitalizations within 42 days of vaccination.
Cohort Season 1 (2007–2008) Season 2 (2008–2009)
LAIV TIV LAIV TIV
n Visitsa Rateb (95% CI)c n Visitsa Rateb (95% CI) n Visitsa Rateb (95% CI) n Visitsa Rateb (95% CI)
Age <24 months 138 2 14.5 (1.7–51.4) 120,901 7279 60.2 (58.9–61.6) 537 19 35.4 (21.4–54.7) 182,365 9416 51.6 (50.6–52.7)
Age  24–59 months
Asthma/recurrent wheezing 633  30 47.4 (32.2–67.0) 17,723 1191 67.2 (63.6–71.0) 2412 102 42.3 (34.6–51.1) 21,656 1431 66.1 (62.8–69.5)
Immunocompromised 12 1 83.3 (2.1–354) 634 107 168.8 (140–200) 89 7 78.7 (32.2–155) 801 111 138.6 (115–164)
ED: emergency department; LAIV: live attenuated inﬂuenza vaccine; TIV: trivalent inactivated inﬂuenza vaccine.
a Includes ED visits and hospitalizations.
b Rate per 1000 vaccinations.
c CIs are provided to indicate precision of estimates and not for statistical comparisons between groups.
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4–59 months with asthma or immunocompromise were low rel-
tive to the general population of children 24–59 months (Table 1).
owever, the rate of vaccination in those with wheezing was com-
arable with that in the general population of children in this age
roup. In all cohorts and in the general population, vaccination rates
ith TIV were higher than with LAIV. From season 1 to season 2,
he rate of LAIV use in the general population increased 4.5-fold,
hereas use in the cohorts of interest, with the exception of the
mmunocompromised group, increased 2.8–3.3-fold. The rate of
se of TIV in all cohorts and within the general population changed
ittle from season 1 to season 2 (Table 1).
Among children younger than 2 years, those with a claim for
AIV in season 1 numbered 138 in total, and 42 were aged <6
onths; in season 2, those with a claim for LAIV numbered 537 in
otal, and 84 were aged <6 months. A detailed claims analysis was
erformed for each subject younger than 6 months, an age for which
o inﬂuenza vaccine is indicated. In 116 of 126 subjects, a claim for
AIV vaccination occurred during a visit in which 1 or more routine
hildhood vaccinations were given in accordance with the Ameri-
an Academy of Pediatrics recommended vaccination schedule. No
ther trends were observed.
Among children identiﬁed with wheezing, the frequency of
ABA and ICS use were generally similar among LAIV and TIV
ecipients in both study seasons (Supplementary Table 1). Among
hildren with asthma, however, there was a trend toward fewer
AIV recipients compared with TIV recipients having ICS dispensed
n the past 12 months (year 1, 52% vs. 61%; year 2, 46% vs. 60%;
AIV vs. TIV, respectively). As would be expected, the proportion
ith ICS use was  lower in children with wheezing compared with
hose with asthma in both study seasons.
Among vaccinated children in the immunocompromised cohort,
t the time of vaccination more than half were classiﬁed as
mmunocompromised owing to recent receipt of systemic corti-
osteroids (SCS). Of the 101 LAIV-vaccinated children in this cohort
uring the 2 seasons, 57 were included owing to a claim for SCS,
4 were included because of a claim for an immunodeﬁciency, 7
ere included owing to a claim for another immunosuppressing
edication, and 3 were included for a malignancy. Immunode-
ciencies included immunity deﬁciency, not otherwise speciﬁed
NOS; n = 15);hypogammaglobulinemia, NOS (n = 6); DiGeorge syn-
rome (n = 5); selective Ig deﬁciency, not elsewhere classiﬁed
n = 5); and other miscellaneous conditions (n = 3).
.1. Safety analysis: emergency department visit or
ospitalization within 42 days postvaccination
In the 2007–2008 season, among the 138 LAIV-vaccinated chil-
ren younger than 24 months, 2 claims for hospitalization or ED
isits occurred within 42 days postvaccination: 1 ED visit for otitis
edia 21 days postvaccination and 1 ED visit for an unspeciﬁed
iral infection 5 days postvaccination. In the 2008–2009 season,
mong 537 LAIV-vaccinated children in this age group, 17 children
xperienced 19 hospitalization and/or ER visits within 42 days of
accination. One child experienced 2 hospitalizations within a span
f several days, both for seizures, and another child experienced
D visits on 2 consecutive days for conjunctival hemorrhage. The
ther 15 children visited the ED once for medical conditions com-
on among young children (e.g., respiratory illness, acute otitis
edia, fever) and were not hospitalized. No lower respiratory ill-
esses were seen in either year. There was no evidence of increased
ates of ED visitation or hospitalization for any diagnosis within 42
ays of vaccination in LAIV recipients compared with TIV recipients
n seasons 1 and 2 (Table 2).
Among the 633 LAIV-vaccinated children with asthma or
heezing in the 2007–2008 season, a total of 30 ED visits or hos-
italizations occurred within 42 days postvaccination (Table 2). (2011) 4947– 4952
Injuries accounted for 7 of the ED visits or hospitalizations, and the
remaining diagnoses consisted of common childhood medical con-
ditions. There was no evidence of increased rates of ED visitation
or hospitalization for any diagnosis within 42 days of vaccination
in LAIV recipients compared with TIV recipients in seasons 1 and
2 (Table 2). Seven LAIV-vaccinated children in the 2007–2008 sea-
son and 24 LAIV-vaccinated children in the 2008–2009 season with
asthma or wheezing visited the ED or were hospitalized within 42
days for a lower respiratory condition known to exacerbate asthma
or wheezing, yielding event rates that were also similar to or lower
than those observed among TIV-vaccinated children with asthma
or wheezing (Table 3).
Among  the 12 LAIV recipients in the 2007–2008 season who
were immunocompromised, there was  1 ED visit (with a diagno-
sis of scalp wound). No events related to infectious diseases were
seen. In the 2008–2009 season, among the 89 LAIV-vaccinated
children with immunocompromise, 7 children experienced an ED
visit (Table 2). Among these 7 children with ED visits, 2 visits
were associated with primary diagnosis codes that were con-
sidered infectious diseases (unspeciﬁed otitis media and croup).
The rate of ED visitation for infectious diseases among LAIV-
vaccinated immunocompromised children was lower than that
observed among TIV-vaccinated immunocompromised children
(22.5 per 1000 for LAIV vs. 60.0 per 1000 vaccinations for TIV). There
were no hospitalizations within this cohort in either season.
4.  Discussion
As of the 2010–2011 inﬂuenza season, approximately 40 million
doses of seasonal trivalent LAIV have been distributed in the United
States. In addition, LAIV has been studied in 73 completed or ongo-
ing clinical trials involving more than 140,000 individuals. Analysis
of data available through the Vaccine Adverse Events Reporting
System (VAERS) for the ﬁrst 2 seasons of LAIV use in the United
States did not identify any unexpected serious risks in children
after LAIV was approved for individuals 5–49 years of age [6].
Additionally, initial data from VAERS for children 24–59 months
of age who  received LAIV during the 2007–2009 seasons did not
identify major new safety concerns [7].
The present study demonstrated that during the 2007–2009
inﬂuenza seasons, the use of LAIV was  low among children younger
than 24 months, children aged 24–59 months with asthma, and
children aged 24–59 months with altered immunocompetence.
The rate of LAIV vaccination in the general population of chil-
dren aged 24–59 months increased 4.5-fold between 2007–2008
and 2008–2009. This increased use in the recommended pop-
ulation likely reﬂects the increased acceptance of LAIV among
providers in the months and years following approval for this
age group. As would be expected, the use of LAIV in nonrecom-
mended populations also increased, yet, with the exception of use
in the immunocompromised cohort, the rising rate of use in these
groups was still lower than that observed in the general population.
This trend and the overall low rate of use suggest that healthcare
providers are generally complying with the product labeling for the
use of LAIV in children aged younger than 5 years.
The rate of LAIV use among children younger than 24 months
was very low. However, given the strong warning against the use of
LAIV in this population and the ease of screening patients’ ages, the
observed rate of LAIV use among children younger than 24 months,
although low, warranted further scrutiny. A review of the claims for
LAIV in children <6 months of age revealed that 92% were submitted
with other vaccine claims, raising the possibility of errors in coding
of other vaccines. The LAIV CPT code (90660) is similar to the codes
for 2 other vaccines (rotavirus [CPT 90680] and pneumococcal con-
jugate [CPT 90669]), which are recommended for use at 2 and 4
P. Tennis et al. / Vaccine 29 (2011) 4947– 4952 4951
Table 3
Number of emergency department visits or hospitalizations for lower respiratory conditions among children with asthma or recurrent wheezing within 42 days of vaccination.
Eventa Season 1 (2007–2008) Season 2 (2008–2009)
LAIV (n = 633) TIV (n = 17,723) LAIV (n = 2412) TIV (n = 21,656)
Visitsb Ratec (95% CI) Visitsb Ratec (95% CI) Visitsb Ratec (95% CI) Visitsb Ratec (95% CI)
Croup 3 4.7 (1.0–13.8) 81 4.6 (3.6–5.7) 5 2.1 (0.7–4.8) 73 3.4 (2.6–4.2)
Pneumoniad 3 4.7 (1.0–13.8) 81 4.6 (3.6–5.7) 3 1.2 (0.3–3.6) 73 3.4 (2.6–4.2)
Bronchiolitis  0 0.0 (0–5.8) 15 0.8 (0.5–1.4) 1 0.4 (0.0–2.3) 18 0.8 (0.5–1.3)
Asthma 1 1.6 (0.0–8.8) 177 10.0 (8.6–11.6) 14 5.8 (3.2–9.7) 243 11.2 (9.9–12.7)
Inﬂuenza 0 0.0 (0–5.8) 7 0.4 (0.2–0.8) 1 0.4 (0.0–2.3) 3 0.1 (0.0–0.40)
Total 7  11.1 (4.4–22.7) 361 20.4 (18.3–22.6) 24 10.0 (6.4–14.8) 410 18.9 (17.2–20.8)
ED: emergency department; LAIV: live attenuated inﬂuenza vaccine; TIV: trivalent inactivated inﬂuenza vaccine.
a Events may  not be mutually exclusive if a child experienced 2 separate diagnoses on separate occasions.
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c Rate per 1000 vaccinations. CI provided to indicate precision of estimates, not f
d One event was  coded as inﬂuenza with pneumonia (ICD-9-CM code 487.0) but c
onths of age, and this similarity may  have contributed to cod-
ng errors. Multiple routine childhood vaccines are given at every
ell-child visit for children up to 24 months of age, and it is possible
hat some of the other 549 LAIV claims (over 2 inﬂuenza seasons in
hildren 6–23 months of age) were also the result of coding errors.
lthough coding errors are rare among claims, a very low rate in
 large population (e.g., all children younger than 24 months) will
esult in a number of falsely recorded vaccinations.
Among children 24–59 months of age with a diagnosis of
sthma, vaccination with LAIV was relatively rare and substantially
ess common than vaccination with TIV. Because the overall rate
f LAIV-vaccination among this cohort was substantially less than
he rate for children in the population recommended for LAIV, it
ppears that clinicians are actively avoiding use of LAIV in patients
ith a history of asthma. For those asthmatic children who  received
AIV, it is not possible to determine the root cause of healthcare
roviders’ choice to administer it. Reasons may  include providers
1) administering the vaccine because of inadequate patient screen-
ng for asthma, (2) believing that the child being vaccinated did not
ave an active diagnosis of asthma based on the provider’s medi-
al judgment, or (3) intentionally vaccinating with LAIV despite the
arning against use based on an assessment of the risks and bene-
ts. It is likely that all 3 phenomena occurred. Diagnosing asthma in
hildren younger than 5 years is especially difﬁcult [8]. The observa-
ion that LAIV-vaccinated children, compared with TIV-vaccinated
hildren, had lower frequencies of recent ICS use in both study
ears and lower frequencies of ED visits and hospitalizations associ-
ted with an asthma diagnosis suggests that providers are actively
voiding LAIV use in more persistent or severe asthmatic patients.
Among  children aged 24–59 months with wheezing, the rate of
accination with LAIV was comparable to that among children of
he same age in the general population in both study years, with a
rend toward less use than in the general population in year 2. These
omewhat similar rates may  be the result of the broad deﬁnition
mployed. The LAIV prescribing information contains a warning
gainst use in children with recurrent wheezing because it can be
 surrogate for asthma in children younger than 5 years, but no
eﬁnition of recurrent wheezing is provided; additionally, because
his warning did not result from an observed adverse outcome and
nstead arose from the lack of safety data in this population, no
AIV-speciﬁc deﬁnition of recurrent wheezing exists in the med-
cal literature. Deﬁnitions for recurrent wheezing that do exist
ave varied considerably, with differences regarding the number
f episodes (3 vs. 4), the time interval (prior 6 months vs. prior
2 months vs. lifetime), and whether episodes must be physician-
onﬁrmed or medically attended [9–15]. The ACIP attempted to
larify this issue by stating that children with recurrent wheezing
ould be identiﬁed as children who have had a single wheezing
pisode noted in the medical record within the past 12 months [3].istical testing.
rized as the potentially more severe pneumonia to avoid double counting.
This deﬁnition was used in the study described here. Our  results
suggest that healthcare providers may  not have judged these sub-
jects as having recurrent wheezing at the time of vaccination, may
have failed to identify the previous relevant history in the med-
ical chart, or may  have intentionally vaccinated these children
with LAIV despite the warning/precaution against use based on an
assessment of the risks and beneﬁts of the vaccine. It is likely that
all occurred.
No safety concerns emerged from the review of ED visits and
hospitalizations within 42 days postvaccination. The higher fre-
quency of ED visits and hospitalizations in TIV-vaccinated cohorts
compared with those vaccinated with LAIV suggests that at the
time of vaccination, the TIV-vaccinated children overall had poorer
health status. This is consistent with providers avoiding LAIV use
and actively encouraging TIV use in high-risk children. Given the
small number of children vaccinated with LAIV in the identiﬁed
cohorts, the current study could only have identiﬁed a large relative
risk of a serious adverse outcome postvaccination. Cumulatively,
the number of children in each cohort across seasons could detect
with 95% probability at least one event occurring at the following
frequencies or greater: among the <24-month-olds, 4.4 per 1000;
among children with asthma or wheezing, 1 per 1000; and among
the immunocompromised, 3 per 1000. The fact that no safety sig-
nals were identiﬁed is consistent with the existing data on LAIV
safety in this age group. As previously mentioned, LAIV was not
approved in children <24 months of age because of an increased
rate of wheezing and hospitalization in a previous study. Because
of the small number of children identiﬁed, the current study lacked
the power to detect similar outcomes in the children <24 months of
age who received LAIV. Other warnings and precautions against the
use of LAIV in individuals 2–49 years of age with high-risk under-
lying medical conditions [16] arise from a lack of data to establish
safety rather than documented safety risks. Clinical studies of LAIV
have been conducted in children with mild to moderate asthma
[10,17], elderly adults with chronic obstructive pulmonary disease
[18], children and adults infected with HIV [19–21], and a small
number of mild to moderately immunocompromised children with
cancer [22] and have not raised concerns of serious safety risks
following LAIV administration.
Existing  anonymized health insurance claims data can be very
useful for monitoring the use and safety of health-related inter-
ventions. They are associated with very large and diverse patient
populations and diverse clinical practices. In addition, neither the
patients nor clinicians are inﬂuenced by the study protocol. How-
ever, there are also several potential limitations inherent to this
approach. Although accuracy of coding for speciﬁc diseases may
vary by disease, the coding for pharmaceuticals and procedures,
such as vaccination, are highly speciﬁc. Whereas this study used
ICD-9-CM diagnosis codes to identify conditions such as asthma
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nd those requiring immunosuppressive therapy, it also applied
oding for pharmaceuticals as a surrogate for asthma or wheez-
ng. In addition, we required 2 diagnosis claims to identify children
ith asthma. This approach helped to exclude individuals for whom
 diagnosis claim was used to indicate medical care performed to
rule out” some condition of interest. Accordingly, the distinction
etween asthma and wheezing was based only upon the available
laims and no data were available on the true clinical disease. This
pproach respected the labels assigned to the children by their
roviders, which are likely the criteria also driving vaccine utiliza-
ion. For example, a large number of children who were dispensed
CS were nevertheless classiﬁed by the study (and apparently by
heir providers) as having wheezing but not asthma.
The use of child-days in the denominators to derive the fre-
uency of vaccination takes into consideration the potential for
hildren to change characteristics during the vaccination season
nd the changing insurance coverage for individual children over
ime; the alternative approach of using number of children in the
enominator would require the assumption of equal duration of
ollow-up throughout the vaccination season, which is unlikely to
e true.
.  Conclusion
In conclusion, over 2 seasons in a large, commercially insured
opulation, vaccination with LAIV was rare among children <24
onths of age or children aged 24–59 months with asthma or
ho were immunocompromised; vaccination with LAIV in chil-
ren aged 24–59 months with wheezing occurred at a rate similar
o that of the general population. Among those few children in these
ohorts who received LAIV despite recommendations to avoid use,
here were no safety signals identiﬁed; however, the number of
accinated children were insufﬁcient to detect rare events.
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